Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23260981 | 0.92 | AR (0.72) | ARHDAC1 | |
| SCHEMBL4021837 | 0.88 | AR (0.74) | ARHDAC1 | |
| SCHEMBL8587964 | 0.88 | AR (0.55) | ARHDAC1 | |
| SCHEMBL13647001 | 0.87 | AR (0.72) | ARHDAC1 | |
| SCHEMBL13647000 | 0.87 | AR (0.74) | ARHDAC1 | |
| SCHEMBL4024956 | 0.86 | AR (0.77) | ARHDAC1 | |
| SCHEMBL8704637 | 0.86 | AR (0.77) | ARHDAC1 | |
| SCHEMBL8516863 | 0.85 | AR (0.79) | ARHDAC1 | |
| SCHEMBL4020463 | 0.85 | AR (0.77) | ARHDAC1 | |
| SCHEMBL30291848 | 0.85 | AR (0.77) | ARHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854716-A4 | ANDROGENIC DIRECTED COMPOSITIONS | BIOPHYSICA FOUNDATION (US) | 1999-04-07 | — | — | EP | claimed |
| EP-0854716-A1 | ANDROGENIC DIRECTED COMPOSITIONS | BIOPHYSICA FOUNDATION (US) | 1998-07-29 | — | — | EP | claimed |
| US-5656651-A | DETECTING TUMOR CELLS | BIOPHYSICA INC. (US) | 1997-08-12 | — | — | US | claimed |
| WO-1997000071-A1 | ANDROGENIC DIRECTED COMPOSITIONS | BIOPHYSICA FOUNDATION (US) | 1997-01-03 | — | — | WO | claimed |
| US-9139565-B2 | Histone deacetylase (HDAC) inhibitors targeting prostate tumors and methods of making and using thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139565-B2 | Histone deacetylase (HDAC) inhibitors targeting prostate tumors and methods of making and using thereof | GEORGIA TECH RESEARCH CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130289085-A1 | HISTONE DEACETYLASE (HDAC) INHIBITORS TARGETING PROSTATE TUMORS AND METHODS OF MAKING AND USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-31 | — | — | US | disclosed |
| US-20130289085-A1 | HISTONE DEACETYLASE (HDAC) INHIBITORS TARGETING PROSTATE TUMORS AND METHODS OF MAKING AND USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-10-31 | — | — | US | disclosed |
| EP-0854716-A4 | ANDROGENIC DIRECTED COMPOSITIONS | BIOPHYSICA FOUNDATION (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0854716-A1 | ANDROGENIC DIRECTED COMPOSITIONS | BIOPHYSICA FOUNDATION (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5656651-A | DETECTING TUMOR CELLS | BIOPHYSICA INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1997000071-A1 | ANDROGENIC DIRECTED COMPOSITIONS | BIOPHYSICA FOUNDATION (US) | 1997-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289085-A1 | HISTONE DEACETYLASE (HDAC) INHIBITORS TARGETING PROSTATE TUMORS AND METHODS OF MAKING AND USING THEREOF | HDAC1, HDAC11, HDAC3 | AR 12/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.